Grab Holdings Ltd. vs State Street SPDR S&P Biotech ETF — how do they compare? Grab Holdings Ltd. trades at $3.63 (market cap $15.26B), while State Street SPDR S&P Biotech ETF trades at $159.95. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals.
| GRAB | XBI | |
|---|---|---|
Market Cap | $15.26B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $6.45 | $164.28 |
52-Week Low | $3.27 | $86.92 |
Enterprise Value | $10.99B | — |
Signals from Pluang's Aura AI — not financial advice
GRAB trades at $3.67, up 0.27% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. Revenue grew to $3.37B in 2025, with net income turning positive at $268M, reflecting improved profitability. The company raised its 2026 guidance after Q2 results, driven by on-demand and financial services growth. Analyst consensus is strongly bullish with an average price target of $5.86, implying 58% upside.
The outlook is positive given consistent earnings outperformance and raised guidance, but risks include high valuation (P/E 34), insider selling, and projected negative cash flow in 2026. Investors should weigh growth momentum against execution challenges in competitive Southeast Asian markets.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Trailing returns across standard periods
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →